Clinical Trials
21 trialsNCT07567222 2026-05-06
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
West China Hospital
Phase 1 Recruiting
NCT04116541 2026-04-24
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03722108 2023-10-16
REGIRI
UNICANCER
Phase 1/2 Terminated
NCT02773524 2022-01-13
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
Phase 3 Unknown
NCT02095054 2021-04-01
Regorafenib and Cetuximab in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01287598 2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1 Completed
NCT01929616 2019-06-25
RegARd-C
Jules Bordet Institute
Phase 2 Completed
NCT02106845 2019-06-07
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Bayer
Phase 1 Completed
NCT01973868 2019-04-09
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Bayer
Phase 1 Completed
NCT02168777 2018-01-26
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Bayer
Phase 1 Terminated
NCT00960258 2017-09-27
Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
Bayer
Phase 1 Completed
NCT02398513 2016-08-01
Regorafenib Phase I Study in Mainland Chinese Patients
Bayer
Phase 1 Completed
NCT01117623 2015-11-18
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Bayer
Phase 1 Completed
NCT02001909 2015-08-13
Effect of Neomycin on the Pharmacokinetics of Regorafenib
Bayer
Phase 1 Completed
NCT01322438 2014-12-19
Effect of Rifampin on the Pharmacokinetics of BAY73-4506
Bayer
Phase 1 Completed
NCT01339104 2014-10-01
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Bayer
Phase 1 Completed
NCT01096030 2013-11-19
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
Bayer
Phase 1 Completed